Recently, to ensure the safety of GLP-1 RA on sarcopenia, a clinical randomized multicenter trial of bimagrumab, an antibody blockade of activin type II receptor inhibitor, alone or in addition to subcutaneous semaglutide is now ongoing (NCT05616013) [113]
Tolerance to GLP-1 medications is not dose-frequency dependent
However, due to the relative expense and scarcity of GLP-1s, online retailers and compounding pharmacies are making alternative formulations available, and many patients are wondering if these alternative formulas are also safe and effective
Developed by a plastic surgeon, this multidimensional treatment targets the appearance of volume loss, deep wrinkles, dehydration, and diminished density including the skin changes associated with GLP-1 use
US National Libary of Medicine